ArticleFrontiers in endocrinology2017
Dose-Dependent and Lasting Influences of Intranasal Vasopressin on Face Processing in Men.
Article in Frontiers in endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT01327027 (Phase 2 Study of Vasopressin Effects on Human Social Communication), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 2 Study of Vasopressin Effects on Human Social Communication
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Effects of arginine vasopressin on human anxiety and associations with sex, dose, and V1a-receptor genotype.Psychopharmacology · 2024Trial
- Vasopressin enhances human preemptive strike in both males and females.Scientific reports · 2019Trial
- Development of an Advanced Drug Delivery System for Protein- and Peptide-Based Therapeutics.Current pharmaceutical design · 2026Review
- Vasopressin as Possible Treatment Option in Autism Spectrum Disorder.Biomedicines · 2023Review
- Modulation of social behavior by distinct vasopressin sources.Frontiers in endocrinology · 2023Review
- Using nanotechnology to deliver biomolecules from nose to brain - peptides, proteins, monoclonal antibodies and RNA.Drug delivery and translational research · 2022Article
- Effects of Intranasal Administration of Oxytocin and Vasopressin on Social Cognition and Potential Routes and Mechanisms of Action.Pharmaceutics · 2022Review
- A Combined Administration of Testosterone and Arginine Vasopressin Affects Aggressive Behavior in Males.Brain sciences · 2021Article
- Role of Oxytocin and Vasopressin in Neuropsychiatric Disorders: Therapeutic Potential of Agonists and Antagonists.International journal of molecular sciences · 2021Review
- Is Oxytocin "Nature's Medicine"?Pharmacological reviews · 2020Review
- Vasopressin in the Amelioration of Social Functioning in Autism Spectrum Disorder.Journal of clinical medicine · 2019Review
- Nanoparticle encapsulation increases the brain penetrance and duration of action of intranasal oxytocin.Hormones and behavior · 2019Article
- Differential Effects of Intranasal Vasopressin on the Processing of Adult and Infant Cues: An ERP Study.Frontiers in human neuroscience · 2018Article
- The Oxytocin-Vasopressin Pathway in the Context of Love and Fear.Frontiers in endocrinology · 2017Review
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
Arginine vasopressin (AVP) and related peptides have diverse effects on social behaviors in vertebrates, sometimes promoting affiliative interactions and sometimes aggressive or antisocial responses. The type of influence, in at least some species, depends on social contexts, including the sex of the individuals in the interaction and/or on the levels of peptide within brain circuits that control the behaviors. To determine if AVP promotes different responses to same- and other-sex faces in men, and if those effects are dose dependent, we measured the effects of two doses of AVP on subjective ratings of male and female faces. We also tested if any influences persist beyond the time of drug delivery. When AVP was administered intranasally on an initial test day, 20 IU was associated with decreased social assessments relative to placebo and 40 IU, and some of the effects persisted beyond the initial drug delivery and appeared to generalize to novel faces on subsequent test days. In single men, those influences were most pronounced, but not exclusive, for male faces, whereas in coupled men they were primarily associated with responses to female faces. Similar influences were not observed if AVP was delivered after placebo on a second test day. In a preliminary analysis, the differences in social assessments observed between men who received 20 and 40 IU, which we suggest primarily reflect lowered social assessments induced by the lower dose, appeared most pronounced in subjects who carry what has been identified as a risk allele for the V1a receptor gene. Together, these results suggest that AVP's effects on face processing, and possibly other social responses, differ according to dose, depend on relationship status, and may be more prolonged than previously recognized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.